Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Verastem Inc (VSTM)

Verastem Inc (VSTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 507,930
  • Shares Outstanding, K 180,758
  • Annual Sales, $ 88,520 K
  • Annual Income, $ -67,730 K
  • 60-Month Beta 0.88
  • Price/Sales 5.64
  • Price/Cash Flow N/A
  • Price/Book 5.62
Trade VSTM with:

Options Overview

Details
  • Implied Volatility 136.79%
  • Historical Volatility 41.89%
  • IV Percentile 66%
  • IV Rank 22.60%
  • IV High 376.60% on 10/29/20
  • IV Low 66.75% on 05/18/21
  • Put/Call Vol Ratio 0.57
  • Today's Volume 296
  • Volume Avg (30-Day) 413
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 2,184
  • Open Int (30-Day) 8,777

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year 0.08
  • Growth Rate Est. (year over year) -212.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +13.00%
on 09/13/21
3.58 -21.09%
on 09/20/21
+0.27 (+10.35%)
since 08/20/21
3-Month
2.48 +13.91%
on 08/20/21
4.87 -41.99%
on 06/22/21
-2.02 (-41.75%)
since 06/21/21
52-Week
1.14 +147.81%
on 10/28/20
4.93 -42.76%
on 06/14/21
+1.52 (+115.65%)
since 09/21/20

Most Recent Stories

More News
Pre-Market Brief: U.S. Stocks to Open Sharply Lower on China Risks

Morning Markets Dec S&P 500 futures this morning are sharply lower by -1.79% at a 1-month low. Concern about contagion from the debt crisis at developer China Evergrande Group is hammering global stock...

JD : 73.75 (-0.54%)
PDD : 94.92 (+0.79%)
BABA : 150.45 (-0.69%)
NTES : 79.59 (-0.59%)
BIDU : 156.85 (+1.52%)
FCX : 30.27 (-2.89%)
CLF : 18.92 (-4.20%)
AA : 44.81 (-7.53%)
X : 21.00 (-3.85%)
TSLA : 736.02 (+0.80%)
WYNN : 79.44 (-3.25%)
LVS : 36.50 (-3.16%)
RIOT : 27.04 (-1.78%)
BTBT : 8.70 (-1.81%)
MARA : 32.54 (-3.98%)
MRTX : 171.11 (-3.57%)
BRKS : 101.66 (-0.77%)
VSTM : 2.89 (+2.85%)
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRAS(TM) (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate...

VSTM : 2.89 (+2.85%)
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting updated data from the ongoing...

VSTM : 2.89 (+2.85%)
Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will present virtually at the following...

VSTM : 2.89 (+2.85%)
Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

--Eliminated Substantially All Outstanding Debt; Expected Cash Runway Until at Least 2024

VSTM : 2.89 (+2.85%)
Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that an abstract detailing updated results from the ongoing...

VSTM : 2.89 (+2.85%)
Axogen, Inc. Appoints John H. Johnson to Board of Directors

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed...

AXGN : 16.10 (+0.75%)
SBBP : 2.0000 (+0.50%)
VSTM : 2.89 (+2.85%)
Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

--Cash Runway Expected Until at Least 2024 to Deliver on Current Programs

VSTM : 2.89 (+2.85%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 16,250 shares of its common...

VSTM : 2.89 (+2.85%)
Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the appointments of Paul Bunn, M.D.,...

VSTM : 2.89 (+2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 4.21
2nd Resistance Point 3.90
1st Resistance Point 3.35
Last Price 2.89
1st Support Level 2.49
2nd Support Level 2.18
3rd Support Level 1.63

See More

52-Week High 4.93
Fibonacci 61.8% 3.49
Fibonacci 50% 3.04
Last Price 2.89
Fibonacci 38.2% 2.59
52-Week Low 1.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar